IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v24y2023i7d10.1007_s10198-022-01533-y.html
   My bibliography  Save this article

The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease

Author

Listed:
  • Zuzana Špacírová

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Escuela Andaluza de Salud Pública (EASP)
    Instituto de Investigación Biosanitaria Ibs.Granada)

  • Stephen Kaptoge

    (University of Cambridge)

  • Leticia García-Mochón

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Escuela Andaluza de Salud Pública (EASP)
    Instituto de Investigación Biosanitaria Ibs.Granada)

  • Miguel Rodríguez Barranco

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Escuela Andaluza de Salud Pública (EASP)
    Instituto de Investigación Biosanitaria Ibs.Granada)

  • María José Sánchez Pérez

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Escuela Andaluza de Salud Pública (EASP)
    Instituto de Investigación Biosanitaria Ibs.Granada
    University of Granada)

  • Nicola P. Bondonno

    (The Danish Cancer Society Research Centre
    Edith Cowan University)

  • Anne Tjønneland

    (The Danish Cancer Society Research Centre
    University of Copenhagen)

  • Elisabete Weiderpass

    (International Agency for Research on Cancer, World Health Organization)

  • Sara Grioni

    (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano)

  • Jaime Espín

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Escuela Andaluza de Salud Pública (EASP)
    Instituto de Investigación Biosanitaria Ibs.Granada)

  • Carlotta Sacerdote

    (Città della Salute e della Scienza University-Hospital)

  • Catarina Schiborn

    (German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE)
    German Center for Diabetes Research (DZD))

  • Giovanna Masala

    (Institute for Cancer Research, Prevention and Clinical Network – ISPRO)

  • Sandra M. Colorado-Yohar

    (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)
    Murcia Regional Health Council
    Univesity of Antioquia)

  • Lois Kim

    (University of Cambridge)

  • Karel G. M. Moons

    (UMC Utrecht, Trecht University)

  • Gunnar Engström

    (Lund University)

  • Matthias B. Schulze

    (German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE)
    German Center for Diabetes Research (DZD)
    University of Potsdam)

  • Léa Bresson

    (Ubisoft France)

  • Concepción Moreno-Iribas

    (Navarra Public Health Institute)

  • David Epstein

    (IdiSNA, Navarra Institute for Health Research
    University of Granada)

Abstract

The objective of this article was to assess the cost-effectiveness of screening strategies for cardiovascular diseases (CVD). A decision analytic model was constructed to estimate the costs and benefits of one-off screening strategies differentiated by screening age, sex and the threshold for initiating statin therapy (“uniform” or “age-adjusted”) from the Spanish NHS perspective. The age-adjusted thresholds were configured so that the same number of people at high risk would be treated as under the uniform threshold. Health benefit was measured in quality-adjusted life years (QALY). Transition rates were estimated from the European Prospective Investigation into Cancer and Nutrition (EPIC-CVD), a large multicentre nested case-cohort study with 12 years of follow-up. Unit costs of primary care, hospitalizations and CVD care were taken from the Spanish health system. Univariate and probabilistic sensitivity analyses were employed. The comparator was no systematic screening program. The base case model showed that the most efficient one-off strategy is to screen both men and women at 40 years old using a uniform risk threshold for initiating statin treatment (Incremental Cost-Effectiveness Ratio of €3,274/QALY and €6,085/QALY for men and women, respectively). Re-allocating statin treatment towards younger individuals at high risk for their age and sex would not offset the benefit obtained using those same resources to treat older individuals. Results are sensitive to assumptions about CVD incidence rates. To conclude, one-off screening for CVD using a uniform risk threshold appears cost-effective compared with no systematic screening. These results should be evaluated in clinical studies.

Suggested Citation

  • Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Es, 2023. "The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1033-1045, September.
  • Handle: RePEc:spr:eujhec:v:24:y:2023:i:7:d:10.1007_s10198-022-01533-y
    DOI: 10.1007/s10198-022-01533-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-022-01533-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-022-01533-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Patrick Royston & Paul C. Lambert, 2011. "Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model," Stata Press books, StataCorp LLC, number fpsaus, December.
    2. David Epstein, 2019. "Beyond the cost‐effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 28(6), pages 801-807, June.
    3. Edmund Jones & David Epstein & Leticia García-Mochón, 2017. "A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models," Medical Decision Making, , vol. 37(7), pages 779-789, October.
    4. Drummond, Michael F. & Sculpher, Mark J. & Claxton, Karl & Stoddart, Greg L. & Torrance, George W., 2015. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 4, number 9780199665884, Decembrie.
    5. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Enoch Yi-Tung Chen & Paul W. Dickman & Mark S. Clements, 2025. "A Multistate Model Incorporating Relative Survival Extrapolation and Mixed Time Scales for Health Technology Assessment," PharmacoEconomics, Springer, vol. 43(3), pages 297-310, March.
    2. Chiranjeev Sanyal & Don Husereau, 2020. "Systematic Review of Economic Evaluations of Services Provided by Community Pharmacists," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 375-392, June.
    3. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    4. Julie A. Campbell & Glen J. Henson & Valery Fuh Ngwa & Hasnat Ahmad & Bruce V. Taylor & Ingrid Mei & Andrew J. Palmer, 2025. "Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modif," PharmacoEconomics, Springer, vol. 43(2), pages 223-239, February.
    5. Christopher M Doran & Irina Kinchin, 2020. "Economic and epidemiological impact of youth suicide in countries with the highest human development index," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-11, May.
    6. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    7. Dongzhe Hong & Lei Si & Minghuan Jiang & Hui Shao & Wai-kit Ming & Yingnan Zhao & Yan Li & Lizheng Shi, 2019. "Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review," PharmacoEconomics, Springer, vol. 37(6), pages 777-818, June.
    8. Yakubu Adole Agada-Amade & Daniel Chukwuemeka Ogbuabor & Eric Obikeze & Ejemai Eboreime & Obinna Emmanuel Onwujekwe, 2024. "Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria," Health Economics Review, Springer, vol. 14(1), pages 1-8, December.
    9. Simon Pol & Paula Rojas Garcia & Fernando Antoñanzas Villar & Maarten J. Postma & Antoinette D. I. Asselt, 2021. "Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting," PharmacoEconomics, Springer, vol. 39(12), pages 1355-1363, December.
    10. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    11. Omar B. Da'ar & Abdi A. Gele, 2023. "Tuberculosis in a weak health system, conflict and fragile zone: The monetary value of human lives lost associated with deaths of persons older than 14 years in Somalia," International Journal of Health Planning and Management, Wiley Blackwell, vol. 38(1), pages 53-68, January.
    12. Anna Nicolet & Antoinette D I van Asselt & Karin M Vermeulen & Paul F M Krabbe, 2020. "Value judgment of new medical treatments: Societal and patient perspectives to inform priority setting in The Netherlands," PLOS ONE, Public Library of Science, vol. 15(7), pages 1-18, July.
    13. McNamara, Simon & Tsuchiya, Aki & Holmes, John, 2021. "Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment," Social Science & Medicine, Elsevier, vol. 269(C).
    14. Enxue Chang & Haofei Li & Wanji Zheng & Lan Zhou & Yanni Jia & Wen Gu & Yiyin Cao & Xiaoying Zhu & Juan Xu & Bo Liu & Mao You & Kejun Liu & Mingsi Wang & Weidong Huang, 2024. "Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis," Applied Health Economics and Health Policy, Springer, vol. 22(4), pages 457-470, July.
    15. Nikolai Mühlberger & Gaby Sroczynski & Artemisa Gogollari & Beate Jahn & Nora Pashayan & Ewout Steyerberg & Martin Widschwendter & Uwe Siebert, 2021. "Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(8), pages 1311-1344, November.
    16. Zachary Tirrell & Alicia Norman & Martin Hoyle & Sean Lybrand & Bonny Parkinson, 2024. "Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory Committee," PharmacoEconomics, Springer, vol. 42(11), pages 1287-1300, November.
    17. Yasuhiro Hagiwara & Takeru Shiroiwa, 2022. "Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches," Medical Decision Making, , vol. 42(5), pages 672-683, July.
    18. Cameron Morgan & Cam Donaldson & Emily Lancsar & Stavros Petrou & Lazaros Andronis, 2024. "Considerations Around the Inclusion of Children and Young People’s Time in Economic Evaluation: Findings from an International Delphi Study," PharmacoEconomics, Springer, vol. 42(11), pages 1267-1277, November.
    19. Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.
    20. Boshen Jiao & Zafar Zafari & Brian Will & Kai Ruggeri & Shukai Li & Peter Muennig, 2017. "The Cost-Effectiveness of Lowering Permissible Noise Levels Around U.S. Airports," IJERPH, MDPI, vol. 14(12), pages 1-10, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:24:y:2023:i:7:d:10.1007_s10198-022-01533-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.